Urology
Volume 75, Issue 5 , Pages 1108-1113.e1 , May 2010

The Loss of Radiographic Enhancement in Primary Renal Cell Carcinoma Tumors Following Multitargeted Receptor Tyrosine Kinase Therapy is an Additional Indicator of Response

  • C. Lance Cowey

      Affiliations

    • Division of Hematology and Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    • ,
  • Julia R. Fielding

      Affiliations

    • Department of Radiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    • ,
  • W. Kimryn Rathmell

      Affiliations

    • Division of Hematology and Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
    • Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    • Corresponding Author InformationReprint requests: W. Kimryn Rathmell, M.D., Ph.D., 450 West Drive, CB 7295, Lineberger Cancer Center, Room 21–237, Chapel Hill, NC 27599

Received 20 May 2009 ,Accepted 28 June 2009.

References 

  1. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883–1887
  2. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  3. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205–216
  5. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–1759
  6. Rubin GD. 3-D imaging with MDCT. Eur J Radiol. 2003;45(suppl 1):S37–S41
  7. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288–3295
  8. van der Veldt A, Meijerink MR, van den Eertwegh AJ, et al. Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. J Clin Oncol. 2009;15S(suppl):Abstract 5044
  9. Amin C, Wallen E, Pruthi RS, et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology. 2008;72:864–868
  10. Thomas AA, Rini BI, Lane BR, et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol. 2009;181:518–523
  11. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, et al. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clin Cancer Res. 2008;14:2431–2436
  12. Robert G, Gabbay G, Bram R, et al. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol. 2009;55:1477–1480
  13. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  14. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–970
  15. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572–4578
  16. de Bazelaire C, Alsop DC, George D, et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:5548–5554

 This study was supported by the Doris Duke Charitable Foundation (WKR) and the UNC Hematology T32 training grant (CLC).

 Julia R. Fielding and W. Kimryn Rathmell are co-corresponding authors.

PII: S0090-4295(09)02392-9

doi: 10.1016/j.urology.2009.06.105

Urology
Volume 75, Issue 5 , Pages 1108-1113.e1 , May 2010

Article Tools

* Image Usage & Resolution